Hematologic Malignancies

Mission Bio, Abiosciences announce collaboration on hematologic cancer research applications

They aim to combine Mission Bio’s multiomics and single-cell DNA capabilities with Abiosciences’ AI technology in finding disease signatures, identifying and addressing mechanisms of therapeutic resistance, and stratifying patients for clinical trials.

December 28, 2022

FDA clears Scopio Labs hematology analysis platform

Tel Aviv, Israel-based Scopio said the X100HT is a full-field digital imaging and artificial intelligence (AI)-enabled platform that combines high throughput with high resolution for hematological analysis.

June 9, 2022

SeekIn receives CE Mark for karyotyping kit

Designed to show copy number alteration patterns in leukemia patients based on shallow whole-genome sequencing, the test can help hematologists make diagnoses and prognostic decisions based on European Leukemia Net, Revised International Prognostic Scoring System, or Revised International Staging System guidelines, according to the vendor.

April 6, 2022

Study recommends screening for adults at risk of multiple myeloma

"We know that in cancers such as breast cancer and lung cancer screening, early detection and early intervention can make a difference in patient survival," senior author Dr. Irene Ghobrial of the Dana-Farber Cancer Institute in Boston said in a statement. "We have shown for the first time that with highly sensitive screening techniques, it may eventually be possible to make a difference in the survival of people at elevated risk for multiple myeloma."

December 10, 2021

AbbVie to deploy Adaptive's clonoSeq test in myeloma trials

Venclexta is currently approved by the U.S. Food and Drug Administration (FDA) for use in treating patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, and in older patients with newly diagnosed acute myeloid leukemia who can't tolerate intensive chemotherapy. It is being tested for a number of additional indications, including multiple myeloma.

December 8, 2019

ArcherDX partners with Illumina on companion tests

Boulder, CO-based ArcherDX is developing a portfolio of IVD tests for assessing targeted therapies based on genetic mutation profiles and monitoring minimal residual disease/treatment response in patients with solid and hematological malignancies.

December 2, 2019

Most Popular

Quest launches long-COVID testing panels for consumers

Ohio, Kentucky doctors convicted in scheme to bill Medicaid for unnecessary urinalysis testing

RNA-seq analysis links protein to spread of pancreatic cancer, reveals potential drug target

Point-of-care test developer Proxim Diagnostics obtains strategic investment from BioMérieux

Quest Diagnostics offers suite of services for transplant patients and living donors

Rapid nirmatrelvir treatment in study reduced long-COVID risk

Foundation, Natera join to develop ctDNA assays

The ctDNA assays will be used by biopharmaceutical and clinical customers who order FoundationOne CDx, a broad companion diagnostic clinically and analytically validated for solid tumors.

September 23, 2019

Page 1 of 1